Deborah Watkins Bruner on Side Effects From Platinum-Based Drugs in Ovarian Cancer

Article

Deborah Watkins Bruner, PhD, RN, FAAN, from the Nell Hodgson Woodruff School of Nursing at Emory University, discusses side effects associated with platinum-based drugs for the treatment of ovarian cancer.

Deborah Watkins Bruner, PhD, RN, FAAN, professor, Nell Hodgson Woodruff School of Nursing, Emory University, discusses side effects associated with platinum-based drugs for the treatment of ovarian cancer.

Recent Videos
5 experts in this video
5 experts in this video
Related Content
Simple line illustration of the female reproductive system with a tumor on the uterine lining, on a light blue background

Pembrolizumab Shows ORR, Tolerability in Previously Treated Gynecologic Cancer

Kristi Rosa
February 11th 2025
Article

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously treated CCGC.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

Lindsay Fischer
June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

yellow background with a white outline indicating ovaries and other gynecological structures

Azenosertib Demonstrates Activity and Tolerability in Ovarian Cancer

Ashling Wahner
February 2nd 2025
Article

Azenosertib (ZN-c3) demonstrated activity as a single agent in heavily pretreated patients with platinum-resistant, cyclin E1-positive ovarian cancer.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News
January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

gynecologic cancer

Lunresertib/Camonsertib Combo Yields Promising Response in Gynecologic Cancers

Chris Ryan
December 26th 2024
Article

Lunresertib plus camonsertib showed promising efficacy in advanced endometrial and platinum-resistant ovarian cancers, with ORRs of 25.9% and 37.5%, respectively.

gynecologic system with cancerous tumor

Sacituzumab Tirumotecan Shows Promise in Pretreated Gynecologic Cancer

Ashley Chan
November 18th 2024
Article

Sacituzumab tirumotecan had antitumor activity in pretreated advanced endometrial and ovarian cancer, data showed.